BIOMAT Database Logo BIOMAT Database Logo

Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. 1994

J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

Human immunodeficiency virus type 1 (HIV-1) recombinant reverse transcriptase (RT) containing lysine (Lys) instead of glutamic acid (Glu) at position 138 proved fully resistant to the inhibitory effect of TSAO derivatives, but retained marked sensitivity to all other HIV-1-specific inhibitors investigated. In contrast, 181 Tyr-->Cys mutated RT lost sensitivity to all HIV-1-specific inhibitors. There was a close correlation between the sensitivity/resistance pattern of HIV-1-specific inhibitors against mutated (138 Glu-->Lys) recombinant HIV-1 RT and mutant virus strains selected for resistance against TSAO-m3T in cell culture and proven to contain the 138-Lys mutation as the sole mutation within the amino acid 50-270 region of their RT.

UI MeSH Term Description Entries
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005971 Glutamates Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure. Glutamic Acid Derivatives,Glutamic Acids,Glutaminic Acids
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase
D013141 Spiro Compounds Cyclic compounds that include two rings which share a single atom (usually a carbon). The simplest example of this type of compound is Spiro[2.2]pentane, which looks like a bow tie. Compounds, Spiro
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine

Related Publications

J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138-->Arg and Tyr-188-->His mutations.
May 1994, Antiviral research,
J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
April 1993, Molecular pharmacology,
J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.
June 1995, Biochemical and biophysical research communications,
J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
January 2004, Molecular pharmacology,
J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
May 1993, Medicinal research reviews,
J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.
September 1991, Journal of virology,
J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
January 2004, Current topics in medicinal chemistry,
J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
January 1995, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie,
J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Human Immunodeficiency Virus type 1 reverse transcriptase.
February 1996, Biological chemistry Hoppe-Seyler,
J Balzarini, and J P Kleim, and G Riess, and M J Camarasa, and E De Clercq, and A Karlsson
Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity.
August 1991, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!